3 Humongous Healthcare Stocks This Week 4-11-14


Published on

This week's biggest health-care stocks

Published in: Healthcare, Business
  • Be the first to comment

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide
  • http://www.fool.com/investing/general/2014/02/04/why-furiex-pharmaceuticals-inc-shares-furiously-do.aspx
  • http://finance.yahoo.com/news/ohr-pharmaceutical-present-16th-annual-131500941.html
  • http://finance.yahoo.com/news/athenahealth-surges-stronger-expected-4q-181446268.html
  • http://investor.furiex.com/releasedetail.cfm?ReleaseID=822849
  • 3 Humongous Healthcare Stocks This Week 4-11-14

    1. 1. 3 Humongous Health-Care Stocks This Week
    2. 2. A lot of health-care stocks took a beating this week. Not all of them, though. Here are the three most humongous health-care stocks over the week ending April 11, 2014.
    3. 3. Shares of the biopharmaceutical firm soared 22% this week. Agios Pharmaceuticals (Nasdaq: AGIO) Source: Yahoo! Finance
    4. 4. • Positive phase 1 preliminary data was announced for cancer drug AG-221. • Agios reported AG-221 was well tolerated but with two possible drug- related severe adverse events. • Clinical results were promising, with multiple complete remissions in patients with blood cancer. • Celgene (Nasdaq: CELG) stands as another winner, as AG-221 is part of a collaboration established between the big biotech and Agios in 2010. Why Agios shares took off
    5. 5. Shares of the biotech climbed 18% higher for the week. Questcor Pharmaceuticals (Nasdaq: QCOR) Source: Yahoo! Finance
    6. 6. • Specialty pharmaceutical company Mallinckrodt (NYSE: MNK) is acquiring Questcor. • Shareholders will receive $30 in cash and 0.897 Mallinckrodt shares for each Questcor share they own. • The deal represents a 27% premium over Questcor’s closing price before the announcement. Why Questcor shot up
    7. 7. Shares of the clinical-stage biotech jumped nearly 18% this week. Bio-Path Holdings (Nasdaq: BPTH) Source: Yahoo! Finance
    8. 8. • No big announcements this week from Bio-Path. • The biotech looks to be rebounding from a sell-off that started in late February. • Bio-Path’s Liposomal Grb-2 is in phase 1 clinical studies targeting several forms of leukemia and myelodysplastic syndrome. Why Bio-Path boomed
    9. 9. • Questcor won’t shoot up significantly, since the price of the acquisition by Mallinckrodt is set. • Bio-Path Holdings could continue its rebound, but major new developments are still in the future. • Agios’ early-stage results for AG-221 show considerable promise . • The partnership with Celgene gives Agios a leg up in continued development of the blood cancer drug. • A possibility also exists that Celgene could use some of its $5.6 billion in cash and short-term investments to scoop up Agios down the road. Best pick to stay humongous?
    10. 10. Find out which stock The Motley Fool’s chief investment officer selected as the top pick for 2014 in our free report!